LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Listă Acțiuni・Organon & Co

Organon & Co

Deschisă

SectorSănătate

13.43 -0.07

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

13.43

Maxim

13.43

Indicatori cheie
By Trading Economics
Venit	351M 146M
Vânzări	-47M 1.5B
P/E Medie Sector	14.43 49.701
EPS	0.71
Randament dividend	0.6
Marjă de profit	10
Angajați	10,000
EBITDA	286M 351M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-8.19% downside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.60% 2.39%
Următoarele câștiguri	4 aug. 2026
Data viitoare de dividende	11 iun. 2026
Următoarea dată ex-dividende	14 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	68M 3.5B
Deschiderea anterioară	13.5
Închiderea anterioară	13.43

Sentimentul știrilor

By Acuity

67%

33%

301 / 345 Clasament în Healthcare

Organon & Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 apr. 2026, 06:09 UTC

Achiziții, Fuziuni, Preluări

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27 apr. 2026, 02:33 UTC

Achiziții, Fuziuni, Preluări

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27 apr. 2026, 01:04 UTC

Achiziții, Fuziuni, Preluări

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7 nov. 2025, 14:41 UTC

Achiziții, Fuziuni, Preluări

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27 apr. 2026, 18:07 UTC

Achiziții, Fuziuni, Preluări

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27 apr. 2026, 15:14 UTC

Achiziții, Fuziuni, Preluări

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27 apr. 2026, 14:56 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 apr. 2026, 13:58 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 apr. 2026, 13:38 UTC

Acțiuni populare

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27 apr. 2026, 12:18 UTC

Achiziții, Fuziuni, Preluări

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27 apr. 2026, 09:22 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27 apr. 2026, 00:38 UTC

Achiziții, Fuziuni, Preluări

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27 apr. 2026, 00:38 UTC

Achiziții, Fuziuni, Preluări

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24 apr. 2026, 20:51 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10 apr. 2026, 20:10 UTC

Achiziții, Fuziuni, Preluări

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr. 2026, 14:39 UTC

Achiziții, Fuziuni, Preluări

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr. 2026, 14:01 UTC

Achiziții, Fuziuni, Preluări

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr. 2026, 09:23 UTC

Acțiuni populare

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Comparație

Modificare preț

Organon & Co Așteptări

Obiectiv de preț

By TipRanks

-8.19% jos

Prognoză pe 12 luni

Medie 12.33 USD -8.19%

Maxim 14 USD

Minim 9 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOrganon & Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Organon & Co - Dist în ultimele 3 luni.

Sentiment

By Acuity

301 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.